Budhram Adrian, Flanagan Eoin P
Department of Clinical Neurological Sciences, Western University, London Health Sciences Centre, London, ON, Canada.
Department of Pathology and Laboratory Medicine, Western University, London Health Sciences Centre, London, ON, Canada.
Mult Scler. 2025 Apr;31(5):505-511. doi: 10.1177/13524585251313744. Epub 2025 Jan 24.
Testing for myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG) is essential to the diagnosis of MOG antibody-associated disease (MOGAD). Due to its central role in the evaluation of suspected inflammatory demyelinating disease, the last 5 years has been marked by an abundance of research into MOG-IgG testing ranging from appropriate patient selection, to assay performance, to utility of serum titers as well as cerebrospinal fluid (CSF) testing. In this review, we synthesize current knowledge pertaining to the "who, what, where, when, why, and how" of MOG-IgG testing, with the aim of facilitating accurate MOGAD diagnosis in clinical practice.
检测髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体(MOG-IgG)对于MOG抗体相关疾病(MOGAD)的诊断至关重要。由于其在疑似炎性脱髓鞘疾病评估中的核心作用,过去5年里,对MOG-IgG检测进行了大量研究,范围涵盖合适的患者选择、检测方法性能、血清滴度的效用以及脑脊液(CSF)检测。在本综述中,我们综合了有关MOG-IgG检测的“何人、何事、何地、何时、为何及如何”的当前知识,旨在促进临床实践中MOGAD的准确诊断。